phenoxybenzamine has been researched along with Ache in 23 studies
Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
Excerpt | Relevance | Reference |
---|---|---|
"Paw skin incision is a well-established postoperative pain model that causes behavioral nociceptive responses and enhanced excitability of spinal dorsal horn neurons." | 1.36 | Serotonin receptors are involved in the spinal mediation of descending facilitation of surgical incision-induced increase of Fos-like immunoreactivity in rats. ( Del Bel, EA; Dias, QM; Prado, WA; Silveira, JW, 2010) |
"Morphine was administered subcutaneously (2." | 1.26 | The contribution of nucleus reticularis paragigantocellularis and nucleus raphe magnus to the analgesia produced by systemically administered morphine, investigated with the microinjection technique. ( Azami, J; Llewelyn, MB; Roberts, MHT, 1982) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 13 (56.52) | 18.7374 |
1990's | 2 (8.70) | 18.2507 |
2000's | 4 (17.39) | 29.6817 |
2010's | 4 (17.39) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Toda, H | 1 |
Maruyama, H | 1 |
Budgell, B | 1 |
Kurosawa, M | 1 |
Silveira, JW | 1 |
Dias, QM | 2 |
Del Bel, EA | 1 |
Prado, WA | 4 |
Cadirci, E | 1 |
Suleyman, H | 1 |
Hacimuftuoglu, A | 1 |
Halici, Z | 1 |
Akcay, F | 1 |
Chang, M | 1 |
Smith, S | 1 |
Thorpe, A | 1 |
Barratt, MJ | 1 |
Karim, F | 1 |
Petronilho, A | 1 |
Reis, GM | 1 |
Fais, RS | 1 |
Tanimoto, T | 1 |
Takeda, M | 1 |
Matsumoto, S | 1 |
Jain, S | 1 |
Sharma, R | 2 |
Snow, AE | 1 |
Tucker, SM | 1 |
Dewey, WL | 1 |
Llewelyn, MB | 2 |
Azami, J | 2 |
Roberts, MH | 1 |
Roberts, MHT | 1 |
Gintautas, J | 1 |
Kraynack, B | 1 |
Hughston, T | 1 |
Thomas, E | 1 |
Racz, G | 1 |
Franco, AC | 1 |
Guimarães, AP | 1 |
Guimarães, FS | 1 |
Manchanda, SK | 1 |
Nayar, U | 1 |
Zheng, P | 1 |
Yang, YR | 1 |
Archer, CB | 2 |
Whittaker, S | 1 |
Greaves, MW | 2 |
Yu, GD | 1 |
Chen, JS | 1 |
Yin, WP | 1 |
Yin, QZ | 1 |
Saarnivaara, L | 1 |
Vorherr, H | 1 |
Meyer, W | 2 |
Fewings, JD | 1 |
Rand, MJ | 1 |
Scroop, GC | 1 |
Whelan, RF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin[NCT00971620] | Phase 2 | 18 participants (Actual) | Interventional | 2008-11-17 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The VAS is a commonly used validated tool for assessment of pain. The 10-cm VAS was used to assess current patient pain/discomfort before and after application of ice to study lesions. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Scale is 0-10. 10 denotes worse pain than 0. (NCT00971620)
Timeframe: Between week 12 and 24
Intervention | Score (Median) |
---|---|
BTX-A | 4.10 |
Placebo/Saline | -0.30 |
Change in worst lesional pain in the past week based on Brief Pain Inventory (BPI) from Week 0 to Week 4 in treated patients versus controls. The BPI uses an arbitrary units on a 0-10 scale. For the purposes of the statistical calculation, a difference of 1 standard deviation between groups at baseline vs. week 4 was considered significant. Any BPI value above zero (no pain) is abnormal. The mean change indicates mean change in pain score. (NCT00971620)
Timeframe: Between week 0 and week 4
Intervention | units on a scale (Mean) |
---|---|
BTX-A | -2.50 |
Placebo/Saline | -1.26 |
The DLQI is a 10-question quality of life survey which has been extensively validated and frequently used in dermatologic disorders such as atopic dermatitis, acne, and psoriasis. Score is 0-30 based on 10 questions. The higher the score, the more quality of life is impaired. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | Units on a scale (Median) |
---|---|
BTX-A | -4.00 |
Placebo/Saline | 0.00 |
AchE staining was scored as 0 (none), 1 (rare), 2 (scattered), or 3 (focal or greater). (NCT00971620)
Timeframe: Week 0 vs. week 12
Intervention | Score (Median) |
---|---|
BTX-A | 1.00 |
Placebo/Saline | 0.00 |
c-fos, a marker of neuronal activation after pain stimulation, was scored as 0 (none), 1 (scattered), 2 (<66% of tumor cells), or 3 (≥66% of tumor cells). (NCT00971620)
Timeframe: Week 0 vs. week 12
Intervention | Score (Median) |
---|---|
BTX-A | -1.00 |
Placebo/Saline | 0.00 |
Change in average pain was assessed by the Brief Pain Inventory (BPI). The BPI is a validated pain assessment tool that assesses severity of pain, location of pain, impact of pain on daily functions, pain medications, and amount of pain relief in the past 24 hours or past week (e.g. scale of 0-10 (worst pain)). (NCT00971620)
Timeframe: Between weeks 0 and week 4
Intervention | Score (Median) |
---|---|
BTX-A | 0.00 |
Placebo/Saline | 0.00 |
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00971620)
Timeframe: 37 months
Intervention | participants (Number) |
---|---|
BTX-A | 4 |
Placebo/Saline | 5 |
"The DLQI is a 10-question quality of life survey which has been extensively validated and frequently used in dermatologic disorders such as atopic dermatitis, acne, and psoriasis. Participants response to the question Over the last week, how itchy, sore, painful or stinging has your skin been? was assessed by the Dermatology Life Quality Index. This outcome refers to a single specific question on the DLQI, so the range for this outcome is 0-3. Lower values in the DLQI indicate less impairment (or greater improvement) in life quality from the skin disease." (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | Units on a scale (Median) |
---|---|
BTX-A | -1.00 |
Placebo/Saline | 0.00 |
The VAS is a commonly used validated tool for assessment of pain. For this measure, a 10-cm VAS was used to assess current patient pain/discomfort before application of ice to study lesions at week 0 and week 4. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Range is 0-10; 0 is no pain and 10 is worst possible pain. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | Score (Median) |
---|---|
BTX-A | 0.00 |
Placebo/Saline | 0.40 |
Pain severity was assessed by the Brief Pain Inventory (BPI). The BPI is a validated pain assessment tool that assesses severity of pain, location of pain, impact of pain on daily functions, pain medications, and amount of pain relief in the past 24 hours or past week (e.g. scale of 0-10 (worst pain)). This outcome was based on a single 0-10 question on the BPI. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | Score (Median) |
---|---|
BTX-A | -2.25 |
Placebo/Saline | -0.75 |
Average pain was determined from a 0-10 scale question on the Brief Pain Inventory (BPI). 10 denotes worse pain. (NCT00971620)
Timeframe: Week 0 score vs. week 4 score
Intervention | percentage of patients (Number) | ||||
---|---|---|---|---|---|
>50% pain reduction | ≤50% pain reduction | No change in pain | Increased pain | Missing | |
BTX-A | 44 | 0 | 22 | 22 | 11 |
Placebo/Saline | 22 | 11 | 33 | 22 | 11 |
The VAS is a commonly used validated tool for assessment of pain. The 10-cm VAS was used to assess current patient pain/discomfort before and after application of ice to study lesions. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Scale is 0-10. 10 = worse pain. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | percentage of patients (Number) | ||||
---|---|---|---|---|---|
>50% pain reduction | ≤50% pain reduction | No change in pain | Increased pain | Missing | |
BTX-A | 33 | 44 | 0 | 22 | 0 |
Placebo/Saline | 33 | 44 | 0 | 22 | 0 |
The VAS is a commonly used validated tool for assessment of pain. The 10-cm VAS was used to assess current patient pain/discomfort before and after application of ice to study lesions. A clinically meaningful change in chronic pain intensity using the VAS has been determined as a reduction of 2 points or 30%. Scale of 0-10. 10 = worse pain. (NCT00971620)
Timeframe: Week 0 vs. week 4
Intervention | percentage of patients (Number) | ||||
---|---|---|---|---|---|
>50% pain reduction | ≤50% pain reduction | No change in pain | Increased pain | Missing | |
BTX-A | 22 | 33 | 0 | 11 | 33 |
Placebo/Saline | 11 | 0 | 11 | 55 | 22 |
2 reviews available for phenoxybenzamine and Ache
Article | Year |
---|---|
[Cliniccal aspects, pathogenesis and therapy of shock due to sepsis caused by gram-negative organisms].
Topics: Adult; Animals; Blood; Chlorpromazine; Diarrhea; Dogs; Electrocardiography; Endotoxins; Escherichia | 1966 |
[Clinical aspects, pathogenesis and therapy of shock due to sepsis caused by gram-negative organisms].
Topics: Adult; Aldosterone; Animals; Blood; Chlorpromazine; Diarrhea; Dogs; Electrocardiography; Endotoxins; | 1966 |
21 other studies available for phenoxybenzamine and Ache
Article | Year |
---|---|
Responses of dorsal spinal cord blood flow to noxious mechanical stimulation of the skin in anesthetized rats.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Anesthesia, General; Animals; Blood Pressur | 2008 |
Serotonin receptors are involved in the spinal mediation of descending facilitation of surgical incision-induced increase of Fos-like immunoreactivity in rats.
Topics: Animals; Atropine; Cholinergic Antagonists; Immunohistochemistry; Ketanserin; Male; Methiothepin; Me | 2010 |
Indirect role of beta2-adrenergic receptors in the mechanism of analgesic action of nonsteroidal antiinflammatory drugs.
Topics: Adrenalectomy; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Animals; Anti- | 2010 |
Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping.
Topics: Administration, Oral; Algorithms; Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Fre | 2010 |
Antinociceptive effect of stimulating the zona incerta with glutamate in rats.
Topics: Analgesics; Animals; Atropine; Glutamic Acid; Haloperidol; Male; Mecamylamine; Methysergide; Microin | 2012 |
Suppressive effect of vagal afferents on cervical dorsal horn neurons responding to tooth pulp electrical stimulation in the rat.
Topics: Action Potentials; Adrenergic alpha-Antagonists; Animals; Dental Pulp; Dose-Response Relationship, D | 2002 |
Analgesia in phasic and tonic pain tests in a pharmacological model of autotomy.
Topics: Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Amphetamine; Analgesia; Animals; Behavio | 2002 |
The role of neurotransmitters in stress-induced antinociception (SIA).
Topics: Animals; Apomorphine; Clonidine; Dopamine; Haloperidol; Kinetics; Male; Neurotransmitter Agents; Nor | 1982 |
The effect of modification of 5-hydroxytryptamine function in nucleus raphe magnus on nociceptive threshold.
Topics: Animals; Brain Stem; Cinanserin; Hot Temperature; Male; Morphine; Pain; Phenoxybenzamine; Raphe Nucl | 1984 |
The contribution of nucleus reticularis paragigantocellularis and nucleus raphe magnus to the analgesia produced by systemically administered morphine, investigated with the microinjection technique.
Topics: Analgesia; Animals; Cinanserin; Male; Microinjections; Morphine; Naloxone; Nociceptors; Pain; Phenox | 1982 |
Activation of coerulospinal systems by nociceptive stimulus.
Topics: Animals; Cats; Electric Stimulation; Female; Hindlimb; Locus Coeruleus; Male; Methysergide; Pain; Ph | 1981 |
Antinociceptive effects of stimulation of discrete sites in the rat hypothalamus: evidence for the participation of the lateral hypothalamus area in descending pain suppression mechanisms.
Topics: Adrenergic alpha-Antagonists; Analgesia; Analgesics, Opioid; Animals; Atropine; Dopamine Antagonists | 1996 |
Modulation of carbachol-induced antinociception from the rat periaqueductal gray.
Topics: Adrenergic alpha-Antagonists; Analgesics; Animals; Anxiety; Bethanechol; Carbachol; Cholinergic Agon | 2000 |
Role of opioid receptors in self-aggression in rats.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Male; Naloxone; Norepinephrine; Pain; Phenoxyben | 1991 |
[Site of analgesic action of aconitine and the relation between its action and the central noradrenergic system].
Topics: Aconitine; Aconitum; Analgesics; Animals; Female; Injections, Intraventricular; Injections, Spinal; | 1988 |
Pharmacological modulation of cold-induced pain in cutaneous leiomyomata.
Topics: Adult; Cold Temperature; Female; Humans; Leiomyoma; Male; Middle Aged; Pain; Phenoxybenzamine; Scopo | 1988 |
Assessment of treatment for painful cutaneous leiomyomas.
Topics: Adult; Humans; Leiomyoma; Male; Nifedipine; Pain; Pain Measurement; Phenoxybenzamine; Skin Neoplasms | 1987 |
[Effect of locus coeruleus stimulation on unit discharge of the hypothalamic arcuate nucleus in rats].
Topics: Animals; Arcuate Nucleus of Hypothalamus; Clonidine; Electric Stimulation; Electrophysiology; Hypoth | 1985 |
Analgesic activity of some sympathetic drugs and their effect on morphine analgesia in rabbits.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic beta-Agonists; Adrenergic beta-A | 1969 |
Catecholamine antagonism to oxytocin-induced milk-ejection.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Animals; Blood Pressure; Catecholamines; Epinephrine; F | 1971 |
The action of nicotine on the blood vessels of the hand and forearm in man.
Topics: Anesthesia, Conduction; Arm; Blood Flow Velocity; Blood Vessels; Denervation; Hand; Hexamethonium Co | 1966 |